Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ZOVIRAX CHICKEN POX POSTMARKETING STUDY WILL ASSESS CLINICAL BENEFIT

Executive Summary

ZOVIRAX CHICKEN POX POSTMARKETING STUDY WILL ASSESS CLINICAL BENEFIT to patients who receive the therapy more than 24 hours after developing symptoms of chicken pox. The Burroughs Wellcome antiviral drug was approved for chicken pox use on Feb. 26 based on studies in which patients were treated within 24 hours of their developing characteristic chicken pox lesions. Further investigation into the timing of administration of Zovirax was suggested by pediatrician Catherine Wilfert, MD, Duke University Medical Center, at a Nov. 12 meeting of FDA's Antiviral Drugs Advisory Committee during which Zovirax was recommended for approval. Burroughs Wellcome plans to provide information on the use of Zovirax for chicken pox directly to pediatricians and primary care physicians. The company said it will also educate consumers about the course of the disease and availability of therapies. The firm declined to elaborate on the nature of its consumer educational program. The cost of a five-day course of Zovirax therapy for chicken pox is $30-$55 (based on the manufacturer-level price for Zovirax). The product is available in 800 mg tablets, 200 mg capsules, and a banana-flavored suspension. A 473 ml bottle of the Zovirax suspension containing 200 mg/5 ml costs $61.79 to wholesalers. To make a significant dent in the estimated 3.5 mil. cases of chicken pox annually in the U.S., Burroughs Wellcome will have to convince physicians that shortening the course of the disease is worth drug treatment. As one FDA panel member said, chicken pox is a "benign rite of passage." In the subpopulation of adult cases, Zovirax is expected to be used more readily. Adult cases constitute fewer than 2% of the 3.5 mil. cases seen annually. Burroughs Wellcome was able to gain approval for Zovirax ahead of Merck's Varivax varicella vaccine. An advisory committee recommended approval for Varivax more than two years ago. However, last November, Merck predicted at least another year before approval.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
UsernamePublicRestriction

Register

PS020537

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel